Abstract

There was a significant time lag between regulatory approval and clinical acceptance of biosimilar infliximab CT-P13 in Ireland.

In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence.

Increased biosimilar medicine usage is of benefit to all stakeholders includin     g patients, prescribers, healthcare payers, and manufacturers.